Skip to content
lifestyle.careersavvy.co.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Entera Bio Ltd.
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
October 13, 2026
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
October 8, 2026
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
October 6, 2026
Correction: Entera to Participate in Upcoming Fall Investor Conferences
August 27, 2026
Entera to Participate in Upcoming Fall Investor Conferences
August 27, 2026
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
August 18, 2026
Entera Announces Second Quarter 2026 Financial Results and Business Updates
August 7, 2026
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
August 4, 2026
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
July 31, 2026
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
July 27, 2026
1
2
Next Page
→